Current Report Filing (8-k)
10 January 2022 - 10:04PM
Edgar (US Regulatory)
0000872589
false
0000872589
2022-01-10
2022-01-10
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): January 10, 2022 (January 10, 2022)
REGENERON PHARMACEUTICALS, INC.
(Exact name of registrant as specified
in its charter)
New York
(State or other jurisdiction of incorporation)
000-19034
|
|
13-3444607
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
777 Old Saw Mill River Road, Tarrytown, New York
|
|
10591-6707
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number,
including area code: (914) 847-7000
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions
A.2. below):
¨ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock – par value $0.001 per share
|
REGN
|
NASDAQ Global Select Market
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02.
|
Results of Operations and Financial Condition.
|
On
January 10, 2022, at the virtual 40th Annual J.P. Morgan Healthcare Conference, Leonard S. Schleifer, M.D., Ph.D., President
and Chief Executive Officer of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”), and
George D. Yancopoulos, M.D., Ph.D., President and Chief Scientific Officer of Regeneron, are providing a corporate update.
The presentation includes information regarding
the Company’s preliminary (unaudited) U.S. net product sales of EYLEA® (aflibercept) Injection of approximately
$5.79 billion for the full year 2021 (based on preliminary (unaudited) fourth quarter 2021 U.S. net product sales of EYLEA of approximately
$1.54 billion).
The
presentation also includes information regarding the Company’s preliminary (unaudited) U.S. net product sales of REGEN-COV®
(casirivimab and imdevimab) of approximately $5.82 billion for the full year 2021 (based on preliminary (unaudited) fourth quarter 2021
U.S. net product sales of REGEN-COV of approximately $2.29 billion).
Item 7.01. Regulation FD Disclosure.
The
information set forth under Item 2.02 of this Current Report on Form 8-K is incorporated by reference herein. A copy of the
presentation referenced in Item 2.02 is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by
reference in this Item 7.01.
The information included in Item 2.02 and the
information included or incorporated in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed”
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall such information and exhibit be deemed incorporated
by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference
in such a filing.
Item 9.01.
|
Financial Statements and Exhibits.
|
(d) Exhibits.
99.1
|
|
Presentation by Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron Pharmaceuticals, Inc., and George D. Yancopoulos, M.D., Ph.D., President and Chief Scientific Officer of Regeneron Pharmaceuticals, Inc., at the virtual 40th Annual J.P. Morgan Healthcare Conference.
|
|
|
|
104
|
|
Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.
|
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
REGENERON PHARMACEUTICALS,
INC.
|
|
|
|
/s/ Joseph J. LaRosa
|
|
Joseph J. LaRosa
|
|
Executive Vice President, General Counsel and Secretary
|
Date: January 10, 2022
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Sep 2023 to Sep 2024